HitGen(688222)2021-10-29 16:00Financial Performance - The company's operating revenue for Q3 2021 was ¥73,169,078.08, representing an increase of 86.95% compared to the same period last year[5]. - The net profit attributable to shareholders for the same period was ¥9,034,650.49, with a year-to-date increase of 103.24% to ¥29,692,579.59[5]. - Basic earnings per share for Q3 2021 was ¥0.02, with a year-to-date increase of 75.00% to ¥0.07[6]. - In the first nine months of 2021, the company achieved operating revenue of RMB 227.31 million, representing a year-on-year growth of 80.50%[16]. - The net profit attributable to shareholders increased by 103.24% year-on-year, with a net profit excluding non-recurring gains and losses rising by 15,632.33%[16]. - The total comprehensive income for the third quarter of 2021 was CNY 25,718,921.05, compared to CNY 15,287,160.29 in the same period of 2020, representing a year-over-year increase of approximately 68.5%[27]. - Basic earnings per share increased to CNY 0.07 from CNY 0.04, reflecting a 75% growth in profitability[27]. Research and Development - Total R&D investment for Q3 2021 was ¥17,661,537.97, a decrease of 37.73% compared to the same period last year[6]. - R&D investment as a percentage of operating revenue decreased by 48.33 percentage points to 24.14% in Q3 2021[6]. - The company has established multiple deep collaborations in drug research and development with various biotech firms, including UPPTHERA and BioAge[17]. - A new molecular structure co-developed with FORMA received registration certification from the American Chemical Society[17]. - The company is advancing its research on artificial intelligence applications in drug discovery, collaborating with Tencent AI Lab on a molecular skeleton transition algorithm[17]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥1,673,795,519.04, reflecting a 1.56% increase from the end of the previous year[6]. - Total liabilities increased to ¥387,574,169.88 in the third quarter of 2021, compared to ¥370,075,489.20 in the same period of 2020, marking an increase of about 4.0%[24]. - The company's total assets as of the end of the third quarter of 2021 amounted to ¥1,673,795,519.04, up from ¥1,648,005,753.49 at the end of 2020[25]. - The total equity attributable to shareholders reached ¥1,286,221,349.16, compared to ¥1,277,930,264.29 in the previous year, reflecting a growth of about 0.6%[24]. - The company’s contract assets increased significantly to ¥19,281,743.68 from ¥3,936,460.48, indicating a growth of approximately 389.5%[23]. Cash Flow - Cash flow from operating activities for the year-to-date period was ¥25,186,166.57, indicating an increase due to higher sales receipts[10]. - The company reported a net cash flow from operating activities growth of 162.99% compared to the previous year[16]. - Cash inflows from operating activities for the first three quarters of 2021 amounted to CNY 246,506,997.61, up from CNY 124,316,725.58 in the same period of 2020, indicating a 98.5% increase[29]. - The net cash flow from operating activities for the third quarter was CNY 25,186,166.57, a significant recovery from a negative cash flow of CNY -39,985,974.19 in the previous year[29]. - Cash inflows from investment activities totaled CNY 1,635,409,651.67, compared to CNY 936,525,126.13 in the same period of 2020, marking a 74.5% increase[30]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 10,345[12]. - Major shareholders included JIN LI with 20.43% ownership and 拉萨经济技术开发区华博医疗器械有限公司 with 14.08% ownership[12]. Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[27].